Overview

To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-30

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA). It consisted of two phases, phase 2 dose exploration trial and phase 3 confirmatory trial.

Phase:

PHASE2

Details

Lead Sponsor:

Suzhou Kintor Pharmaceutical Inc,

Collaborator:

Suzhou Koshine Biomedica, Inc.

Treatments:

BID protein, human